 This multicenter phase 2 clinical trial is designed to assess safety of P28GST protein 28 Kd glutathion S Transferrase, aiming to control inflammation in moderate Crohns Disease CD, before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from Schistosoma with potent immunogenic and anti-oxidant properties. Based on experimental evidence of its anti-inflammatory properties, the investigators hypothesized that administration of P28GST could protect against recurrence after intestinal resection surgery in CD. 